<DOC>
	<DOCNO>NCT00462397</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , carboplatin , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving combination chemotherapy together radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give paclitaxel together carboplatin follow cisplatin radiation therapy work treat patient stage IB , stage II , stage III , stage IVA cervical cancer .</brief_summary>
	<brief_title>Paclitaxel Carboplatin Followed Cisplatin Radiation Therapy Treating Patients With Stage IB , Stage II , Stage III , Stage IVA Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate , term clinical radiologic response 12 week completion study therapy , patient stage IB2-IVA cervical cancer treat neoadjuvant chemotherapy comprise dose-dense paclitaxel carboplatin follow radical chemoradiotherapy comprise concurrent cisplatin radiotherapy . Secondary - Determine response rate patient treat neoadjuvant chemotherapy regimen . - Determine toxicity neoadjuvant chemotherapy regimen patient . - Assess progression-free survival patient treat regimen . - Determine overall survival patient treat regimen . OUTLINE : This multicenter study . - Neoadjuvant chemotherapy : Patients receive neoadjuvant chemotherapy comprise paclitaxel IV 1 hour carboplatin IV 30 minute day 1 . Treatment repeat weekly 6 course absence disease progression unacceptable toxicity . - Chemoradiotherapy : Beginning week 7 , soon blood count recover , patient receive cisplatin IV 1 hour day 1 . Treatment repeats weekly 4-6 course absence disease progression unacceptable toxicity . Patients also undergo concurrent radiotherapy comprise pelvic external beam radiotherapy daily 5½ week ( 5 week patient positive para-aortic lymph node ) 2 application high-dose rate intracavitary brachytherapy low- medium-dose rate brachytherapy . Patients parametrial pelvic sidewall disease extension also undergo external boost radiotherapy 3 day . After completion study therapy , patient follow periodically 2 year . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm carcinoma cervix , include follow subtypes : Squamous cell carcinoma Adenocarcinoma Adenosquamous cell carcinoma Locally advance disease ( i.e. , FIGO stage IB2IVA disease ) Stage confirm examination anesthesia , cystoscopy , sigmoidoscopy biopsy suspicious lesion bladder , vagina , rectum Disease suitable treatment radical intent use chemoradiotherapy PATIENT CHARACTERISTICS : ECOG performance status 01 Platelet count &gt; 100,000/mm^3 Hemoglobin &gt; 12.5 g/dL WBC &gt; 3,000/mm^3 Absolute neutrophil count &gt; 1,500/mm^3 Bilirubin &lt; 1.25 time upper limit normal ( ULN ) Glomerular filtration rate ( GFR ) normal ethylenediaminetetraacetic acid ( EDTA ) OR creatinine clearance ≥ 60 mL/min Placement ureteric stent require patient hydronephrosis , regardless renal function ALT AST &lt; 2.5 time ULN Not pregnant nursing Negative pregnancy test No prior diagnosis cancer , except basal cell skin cancer No active cardiac disease Deemed fit receive chemoradiotherapy ECG normal PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
</DOC>